Does the data for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?
Community PollStarted
Do you plan to incorporate pembrolizumab in the treatment of platinum-resistant ovarian cancer in conjunction with paclitaxel +/- bevacizumab?
64 physicians have voted
Join Mednetto vote and see how they answered.